The total return over the past 12 months is +19.85% vs. +22.53% for the S&P 500. So far it's up +9.87% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +19.85% | +5.65% | (3.36%) | +9.45% | +15.34% | +17.43% |
| Total Return CAGR | +19.85% | +5.65% | (3.36%) | +9.45% | +15.34% | +17.43% |
| Revenue CAGR | +14.55% | +6.29% | +5.75% | +9.03% | +9.92% | +9.74% |
| Net Income CAGR | (75.75%) | (10.24%) | +5.45% | +6.64% | +10.18% | +11.39% |
| EPS CAGR | (75.04%) | (9.22%) | +6.87% | +9.10% | +12.37% | +15.13% |
| Free Cash Flow CAGR | +135.83% | +28.09% | +6.41% | +12.79% | +14.30% | +12.87% |
| Operating Cash Flow CAGR | +116.42% | +22.30% | +3.58% | +11.04% | +13.29% | +11.83% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Edwards Lifesciences Corporation (EW)
| Year | Start price | End price | EW Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $85.25 | $93.66 | +9.87% | +13.60% | (3.73%) |
| 2025 | $74.03 | $85.25 | +15.16% | +17.72% | (2.56%) |
| 2024 | $76.25 | $74.03 | (2.91%) | +24.89% | (27.80%) |
| 2023 | $74.61 | $76.25 | +2.20% | +26.19% | (23.99%) |
| 2022 | $129.55 | $74.61 | (42.41%) | (18.17%) | (24.24%) |
| 2021 | $91.23 | $129.55 | +42.00% | +28.74% | +13.26% |
| 2020 | $77.76 | $91.23 | +17.32% | +18.37% | (1.05%) |
| 2019 | $51.06 | $77.76 | +52.31% | +31.22% | +21.09% |
| 2018 | $37.57 | $51.06 | +35.90% | (4.56%) | +40.46% |
| 2017 | $31.23 | $37.57 | +20.29% | +21.70% | (1.41%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
